Handbook of Melatonin-Based Therapy and its Applications provides pharmaceutical researchers and health professionals with a comprehensive reference on the applications of melatonin in the therapeutic setting. Succinct, meticulously organized, and expertly written, this book addresses all essential aspects. It starts with an overview of safe use of melatonin, translational aspects, and its prospection. The next section of the book covers a variety of clinical applications, including dosage, pharmacokinetics and pharmacodynamic profiles, toxicity, and principles of action. The chapters in this section cover applications to both adults and pediatric patients suffering from conditions like skin cancers, GI issues, psychiatric, hepatic and ocular conditions.
This is a comprehensive resource for pharmaceutical scientists and health professionals involved in developing therapies and applying them to patients. Researchers in the fields of medicine, biology, neuroscience, and pharmacology conducting studies related to melatonin-based will benefit from insights into the latest research findings, clinical trials, and therapeutic approaches.
This is a comprehensive resource for pharmaceutical scientists and health professionals involved in developing therapies and applying them to patients. Researchers in the fields of medicine, biology, neuroscience, and pharmacology conducting studies related to melatonin-based will benefit from insights into the latest research findings, clinical trials, and therapeutic approaches.
Table of Contents
1. Physiology and Safety of melatonin2. Translational melatonin in preclinical models
3. Melatonin and COVID-19
4. Obtaining phytomelatonin and other bio(logical)-melatonin: sources and therapeutic applications
5. Melatonin as a Therapy for Neonatal Encephalopathy: The journey to clinical trials
6. Melatonin Gastroprotection by melatonin: an emerging concept and underlying mechanisms
7. Melatonin as a therapeutic in the skin
8. The use of melatonin in oxidative stress of the newborn
9. Synergistic impact of melatonin on colorectal cancer
10. Melatonin in Oncology: Unveiling its Potential in Prostate Cancer
11. The use of melatonin in pediatric perioperative care
12. Exploring melatonin as a therapeutic approach for mustard vesicants
13. Epigenetic Modulation by Melatonin: Clinical Implications and Therapeutic Prospects
14. Why Melatonin Administration might be harmful during the mounting of a defense response
15. New galenic formulations of melatonin and therapeutic applications
16. Melatonin, sleep and mood disorders
17. Melatonin and neurodegenerative diseases
18. Melatonin and autism spectrum disorders
19. Melatonin and andrology
20. Melatonin and hepatic injury
21. Melatonin treatment against experimental optic Neuritis and glaucoma
Authors
Alejandro Romero Mart�nez Professor, Department of Toxicology, Complutense University of Madrid, Madrid, Spain. Alejandro Romero Mart�nez, PhD in BiologicalSciences from the University of Vigo
(2000), is a Tenured Professor in Toxicology
at the University Complutense of Madrid.
His research activity has resulted in 105
Journal Citation Reports (JCR) articles (h-index
38). He is also the coauthor of 12 international
book chapters and 4 national. Moreover,
he coauthors >50 international and
>40 national congress communications and
2 patents. He has supervised two doctoral
theses. He is a member of 4 editorial
committees and has acted as reviewer/
evaluator of 72 international journals in his
specialty with JCR relative quality index. He
combines his interest and background on
molecular toxicology and neuroprotection
studies of new molecules with therapeutic
interest against neurodegeneration and focuses
on novel melatonin-based therapies.
He has made important contributions in
cell/molecular biology of new multitarget
compounds synthesized against key targets
in Alzheimer's disease and advances in the
knowledge of melatonin as a pleiotropic
agent against several pathologies and
mechanisms of toxicity. Dr. Martinez led the
MELVES project (medical countermeasures
program SYP41804) to test melatonin as a
potential health support measure for treatment
and prophylaxis. Remarkably, the
Spanish Ministry of Defence-General Directorate
of Armament and Material/SDG
PLATIN has displayed interest by selecting
his project. He has collaborated as an
external reviewer for the Czech Science
Foundation and Medical Research Council's
Developmental Pathway Funding Scheme
(DPFS). Moreover, he is a member of the
Spanish Association of Toxicology (AETOX)
since January 2011, and certified as a European
Registered Toxicologist (ERT). Eva Ramos Alonso Universidad Complutense de Madrid, Madrid, Spain. Dr. Ramos Alonso began her scientific career as an undergraduate student at the Complutense University of Madrid (UCM), where she graduate in Pharmacy in 2007. In 2010 she received her Ph.D. with First Class Honours. She acquired a wide experience in alternative research to animal experimentation, with in silico techniques and in vitro tests applied to assess the safety or toxicological profile, as well as, the efficacy of a wide variety of chemical products and new molecules with therapeutic interest against neurodegeneration.
She is currently a Tenured Associate Professor, She combines her interest and background in molecular toxicology and neuroprotection studies. She has made important contributions in i) Molecular action mechanisms of Xenobiotics ii) New toxicological data on several xenobiotics (Chemical warfare agents, pyrethroids, metals, mycotoxins...), and iii) Advances in the research of melatonin as a pleiotropic agent. Francisco L�pez-Mu�oz Camilo Jos� Cela University, Madrid, Spain.
Francisco L�pez-Mu�oz is PhD Degree in Medicine (Complutense University), and PhD Degree in Spanish Language and Literature (University of Alcal�). He is a specialist in Pharmaceutical Medicine. Currently he is Professor of Pharmacology, Vice Chancellor of Research and Science, and Chairman of the Research Ethics Committee at Camilo Jos� Cela University (Madrid), and Research Fellow at "Hospital 12 de Octubre� Research Institute (Madrid, Spain). He has participated as Guest Professor or as Director in more than 150 postgraduate and doctoral courses at different national and international academic centers. He has supervised 22 PhD theses, has participated in 47 research projects, and acts as evaluator for several European Agencies. He is editor/author of 30 books and author of 235 chapters of books and 480 articles related to the psychopharmacology and other topics, and has been or is member of several scientific societies (including Collegium Internationale Neuro-Psychopharmacologicum), and editorial boards. He is Director of the International Editorial Council of the Collection "Medical Humanities: Culture, Art, Science and Health� (Delta Publications, Madrid).
